Pfizer (PFE) PT Raised to $59 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pfizer (PFE) Stock: Cowen Sees Additional $50 Billion in 2022 Sales From Covid Vaccine and Oral Pill, Raises Price Target
December 20, 2021 8:56 AM ESTCowen analyst Steve Scala raised the price target on Pfizer (NYSE: PFE) to $70.00 per share from the prior $56.00 to reflect raised estimates.
The analyst raised Comirnaty sales estimate to $35 billion (vs $31 billion previously) and established a Paxlovid sales forecast of $15 billion (vs $0 previously) in 2022. The company said earlier... More
